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Abstract
Extraskeletal myxoid chondrosarcoma (EMC) is a rare sarcoma histotype with uncertain differentiation. EMC
is hallmarked by the rearrangement of the NR4A3 gene, which in most cases fuses with EWSR1 or TAF15.
TAF15-translocated EMC seem to feature a more aggressive course compared to EWSR1-positive EMCs, but
whether the type of NR4A3 chimera impinges upon EMC biology is still largely undefined. To gain insights on
this issue, a series of EMC samples (7 EWSR1-NR4A3 and 5 TAF15-NR4A3) were transcriptionally profiled. Our
study unveiled that the two EMC variants display a distinct transcriptional profile and that the axon guidance
pathway is a major discriminant. In particular, class 4–6 semaphorins and axonal guidance cues endowed with
pro-tumorigenic activity were more expressed in TAF15-NR4A3 tumors; vice versa, class 3 semaphorins, considered
to convey growth inhibitory signals, were more abundant in EWSR1-NR4A3 EMC. Intriguingly, the dichotomy in
axon guidance signaling observed in the two tumor variants was recapitulated in in vitro cell models engineered to
ectopically express EWSR1-NR4A3 or TAF15-NR4A3. Moreover, TAF15-NR4A3 cells displayed a more pronounced
tumorigenic potential, as assessed by anchorage-independent growth. Overall, our results indicate that the type of
NR4A3 chimera dictates an axon guidance switch and impacts on tumor cell biology. These findings may provide
a framework for interpretation of the different clinical–pathological features of the two EMC variants and lay
down the bases for the development of novel patient stratification criteria and therapeutic approaches.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Extraskeletal myxoid chondrosarcoma (EMC) is a rare
sarcoma histotype (<3% of soft tissue sarcomas) that
primarily occurs in the extremities of adults [1]. EMC
is defined as ‘an indolent, but resilient and capricious
tumor’ [2], with a propensity to relapse even after
several years from diagnosis and up to 40% risk of
metastases [3,4]. Surgery is the mainstay treatment
for primary localized EMC, while advanced disease
requires medical therapy. Unfortunately, chemotherapy
has a limited efficacy over time [4,5] but promising
results have been recently achieved with antiangio-
genetics. Specifically, we recently reported on the long
lasting activity of the tyrosine kinase inhibitor sunitinib
in a retrospective series of 10 advanced EMC [3], and
a European phase 2 study is investigating the activity of
pazopanib (NCT02066285).
Originally considered a cartilaginous neoplasm [1,6],
EMC is currently classified as a tumor of uncertain
differentiation [1]. Although the histogenesis of EMC
remains unclear, different reports have highlighted
the presence of neural-neuroendocrine features as
evidenced by occasional staining for neuron-specific
enolase, chromogranin, synaptophysin and/or iden-
tification of dense-core granules on ultrastructural
analysis [7–10]. Neural-neouroendocrine features were
reported as enriched in EMC also in a microarray study
comparing this tumor to other soft tissue sarcomas
[11]. Most EMC are hypocellular and classified as
low-grade neoplasms. However, high-grade EMC are
also described and characterized by hypercellularity
and occasional rhabdoid morphology that correlates
with adverse clinical outcomes [1,12].
A distinctive feature of EMC is chromosome rear-
rangement involving the 9q22 region harboring the
NR4A3 gene. In most cases, the whole NR4A3 coding
region is fused downstream of the N-terminal transacti-
vation domain of EWSR1, less frequently to the same
domain of TAF15. Occasional fusions with TCF12,
TFG, HSPA8 have also been reported [1,13,14].
NR4A3 is a poorly characterized protein that, together
with NR4A1 and 2, constitutes the NR4A family of
orphan nuclear hormone receptors. Although there
is a putative ligand binding domain, no endogenous
ligand has been identified. NR4A proteins are involved
in the control of different biological processes such
as cell proliferation, migration, apoptosis, neuron
development, axonogenesis and angiogenesis, and
appear as emerging players in the context of cancer
[15,16]. NR4A proteins, whose activities are context
and tissue specific, localize both in the nucleus and
in the cytoplasm. In the nucleus, they are reported
to act as a transcription factors via binding to NBRE
(NGF-induced B factor-response element) and related
consensus sequences on DNA; in the cytoplasm, they
have been shown to intersect different molecular path-
ways by protein–protein interactions, and increased
cytosolic NR4A1 or NR4A2 protein levels have been
associated with tumor aggressiveness [16–18]. As
EMC chimeras retain the DNA binding domain of
NR4A3, they potentially recognize NBRE consensus
sites [19,20]. EWSR1 and TAF15 are members of the
FET family of RNA binding proteins that participate,
with their N-terminus, to the generation of a number of
fusion oncoproteins involved in sarcomas [21].
Recent reports suggest that TAF15-translocated
EMC feature a more aggressive behavior compared to
the EWSR1-translocated counterpart [12]. However,
whether and how the type of NR4A3 chimera affects
the tumoral phenotype is still largely undefined. To
shed light on this issue and ideally provide grounds for
better risk classification criteria and targeted therapeutic
approaches, we molecularly profiled a set of EMC
samples and cell models expressing either the EWSR1
or the TAF15 fusion transcript.
Materials and methods
Tumor series
The study was conducted on a series of 12 EMC
retrieved from the pathology files of Fondazione IRCCS
Istituto Nazionale dei Tumori (Milano), the Treviso
Regional Hospital and the IRCCS Istituto Ortopedico
Rizzoli (Bologna) and approved by the appropriate
Institutional Review Boards. Clinicopathological fea-
tures of the series are summarized in Table 1. All
patients were treated with surgery for disease originating
from soft tissues. Pathological diagnosis was centrally
reviewed by two expert pathologists (APDT and SP) and
the rearrangement of NR4A3 was confirmed by FISH.
Immunohistochemistry and FISH analyses
Representative 2-μm sections of formalin-fixed,
paraffin-embedded (FFPE) surgical samples were
immunostained for Semaphorin 4D, Plexin A4, Synap-
tophysin, Reelin, Nestin, NCAM1/CD56 and Glial
Fibrillary Acidic Protein as detailed in supplemen-
tary material, Supplementary materials and methods.
FISH analyses were performed on FFPE sections
using the probes indicated in supplementary mate-
rial, Supplementary materials and methods. At least
Table 1. EMC clinicopathological features
CASE # NR4A3 partner Gender Age at the diagnosis Tumor site
1 EWSR1 F 48 Upper leg
2 EWSR1 M 48 Groin
3 EWSR1 M 55 Upper leg
4 EWSR1 M 57 Upper leg
5 EWSR1 F 60 Upper leg
6 EWSR1 M 71 Buttock
7 EWSR1 M 76 Upper leg
8 TAF15 M 50 Buttock
9 TAF15 M 62 Lower leg
10 TAF15 M 58 Buttock
11 TAF15 M 39 Lower leg
12 TAF15 M 50 Lower leg
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50 non-overlapping nuclei were scored at ×100
magnification.
Whole transcriptome sequencing and gene
functional annotation
Tumor sections with >70% tumor nuclei were used
for transcriptional analysis. Total RNA was isolated
from FFPE EMC as in [22] and from frozen samples
as in [3]. RNA from cell cultures was extracted using
the TRIzol reagent (ThermoFisher Scientific, Waltham,
MA, USA). RNA-sequencing (RNA-Seq) was used for
transcriptional profiling. For FFPE samples and cell
cultures RNA-Seq libraries were prepared as in [22]
and sequenced on a Hiseq1000 Illumina apparatus to an
average of 70-million paired-end reads per sample. Raw
sequence data quality was assessed using the FastQC
software (http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/). STAR, HTSeq, and DEseq2 were used
for readmapping, quantification, gene-level exploratory,
and differential expression analysis [23–25]. Raw and
processed sequencing data are available at http://
opendocuments.cro.it/cod/handle/item/9167.
DESeq2 was used for principal component analysis
(PCA). Biomedical Genomics Workbench (QIAGEN-
Bioinformatics-v4.1.1, Qiagen, Hilden, Germany) was
used for additional quantifications (transcripts per mil-
lion, TPM) and hierarchical clustering. For fresh-frozen
samples libraries were prepared and analyzed as in
[3]. Over-representation analyses (ORA) were per-
formed with DAVID (v6.7) [26] and WebGestalt-2017
(ORA-WebGestalt) [27]. Gene set enrichment anal-
yses (GSEA) were performed with WebGestalt-2017
(GSEA-WebGestalt) [27] and GSEA-Broad Institute
(v3.0) [28]. Ingenuity pathway analysis (IPA) (QIA-
GEN) [29] and NetworkAnalyst [30] were used for
further functional annotations. Details are provided in
supplementary material, Supplementary materials and
methods.
Cells and constructs
tBJ/ER were maintained and engineered by retro-
viral infections as described [31,32]. The following
cDNAs, cloned into the retroviral PLPCX vector (Clon-
tech Takara Bio Inc., Kusatsu, Japan), were used:
full-length NR4A3; E-N, corresponding to EWSR1
(exons 1–12)-NR4A3 (exons 3–8); T-N, corresponding
to TAF15 (exons 1–6)-NR4A3 (intron 2–exon 8) and
T-N*, corresponding to the commonest TAF15 (exons
1–6)-NR4A3 (exons 3–8) fusion. Both T-N and T-N*
encode the whole coding sequence of NR4A3 (exons
3–8); T-N retains a short cryptic exon located in NR4A3
intron 2 (ENST00000395097.6 isoform), thus encoding
25 additional amino acids prior to theNR4A3ATG. Both
untagged and Strep-tagged versions of these plasmids
were used.
For transcriptional profiling 4 (E-N and T-N) or 3
(NR4A3) biological replicates were generated by sep-
arate viral infections. Anchorage-independent growth
assay was carried out in soft agar-semisolid medium
as previously described [31]. Colonies were scored at
×100 magnification 8 days after plating and size and
number of colonies/field (cutoff size> 30 μm) were
estimated. A minimum of 20 non-overlapping fields of
three independent replicates were scrutinized blindly by
two investigators.
Protein analysis
For western blot analysis, protein lysates were generated
and separated on SDS-PAGE as detailed in supplemen-
tary material, Supplementary materials and methods.
Membranes were probed with the following antibodies:
anti-NR4A3 Mouse MoAb clone H7833 (R&D Sys-
tems, Minneapolis, MN, USA), Mouse MoAb clone
OTI5C2 (Origene, Rockville, MD, USA) targeting
the N-terminus and C-terminus of NR4A3, respectively;
anti-Strep-Tag mouse MoAb (clone GT661, AbCam,
Cambridge, UK); anti-POLR3A MoAb (Rabbit MoAb,
clone D5Y2D, Cell Signaling Technology, Danvers,
MA, USA) was used to normalize total protein load.
Quantitative RT-PCR (RT-qPCR) and transcriptional
array
Relative mRNA levels of NR4A3, related fusions and of
a set of SEMAs were assessed by RT-qPCR in tBJ/ER
cell models. At least three independent biological repli-
cates were analyzed. A targeted transcriptional array
analysis was performed on 6 EMC for which suitable
material was available. Methodological details on these
procedures are in supplementary material, Supplemen-
tary materials and methods.
Chromatin affinity purification-quantitative PCR
(ChAP-qPCR)
The MatInspector software was employed to identify
putative NR4A3 consensus sites (NBRE) [33]. Chro-
matin affinity purification (ChAP) on tBJ/ER cells
expressing Strep-tagged NR4A3, EWSR1-NR4A3 or
TAF15-NR4A3 was performed as detailed in sup-
plementary material, Supplementary materials and
methods. Precipitated DNA was quantified by qPCR
with primers targeting the identified SEMA3C regula-
tory region. The fraction of the target DNA recovered
from the input was measured by comparing the thresh-
old cycle (CT) of the precipitated sample to a dilution of
its own input, and was expressed as relative enrichment.
The background was estimated by PCR amplification
of an unrelated genomic region (GAPDH exon 1).
Results
EWSR1 and TAF15-rearranged EMC feature a
different gene expression pattern
To gain insight into EMC pathobiology, seven
EWSR1-NR4A3 and five TAF15-NR4A3 EMC were
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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Figure 1. Transcriptome profiling of EMC. (A) Principal component analysis of the transcriptome of EWSR1-NR4A3 (red) and TAF15-NR4A3
(blue) rearranged EMC. (B) Z-Score normalized heat map of the expression values (log2 transformed) of the top 500 differentially expressed
genes in TAF15-NR4A3 and EWSR1-NR4A3 EMC. Sample (top) and gene (left) dendrograms are shown. Sample ID number and NR4A3
fusion partner are indicated. The color bar indicates the Z-score and reflects the relative gene expression level, from blue (low), white
(medium) to red (high). Gene cluster 1 consists of the genes overexpressed in EWSR1-NR4A3 EMC; gene cluster 2, the genes overexpressed
in TAF15-NR4A3 EMC. (C) Log2 fold change of the axon guidance molecules differentially expressed in the two EMC variants. Black and
grey bars indicate genes underexpressed and overexpressed, respectively, in TAF15-NR4A3 versus EWSR1-NR4A3 tumors.
transcriptionally profiled by RNA-Seq (Table 1). For
five samples (four EWSR1 and one TAF15) frozen
material was also profiled, yielding similar results to
the matched FFPE counterpart (data not shown). PCA
of the transcriptome showed that, although there was
not a net demarcation between TAF15 and EWSR1
EMC, the majority of EWSR1 tumors (5/7) tended
to separate from the TAF15 EMC group along the
Principal Component 1 (Figure 1A). Hierarchical clus-
tering of the top 500 genes with differential expression
between TAF15 and EWSR1 EMC (false discovery
rate [FDR]< 0.1) provided a preliminary overview of
the transcriptome pattern (Figure 1B). This scrutiny
identified two major gene clusters: cluster 1 included
156 genes overexpressed in EWSR1 EMC; cluster 2
consisted of 344 genes expressed at higher levels in
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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Table 2. Representative functional categories of the genes differentially expressed in TAF15-NR4A3 versus EWSR1-NR4A3 EMC and in
T-N versus E-N cell models
Sample Method Tool GO biological process/pathway FDR
EMC ORA WebGestalt Neuron projection guidance 1.3e−3
Semaphorin-Plexin signaling 1.6e−3
Axon development 1.8e−3
Blood vessel morphogenesis 1.5e−2




GSEA WebGestalt Muscle system process 1.1e−3
Axon development 1.7e−2
Neuron projection guidance 2.3e−2
Nerve development 2.0e−1
GSEA-Broad Neuron projection morphogenesis 4.5e−3
Axon 4.0e−2
Extracellular space 1.8e−1
Muscle system process 1.6e−1
IPA IPA Canonical pathways Axonal guidance signaling 1.1e−5
Glutamate Receptor Signaling 2.0e−4
Reelin signling in neurons 2.0e−3
Ephrin receptor signaling 3.6e−3
Cell models ORA WebGestalt Cell growth 2.0e−5
Neural tube development 4.1e−5
Blood vessel morphogenesis 5.1e−5
DAVID Neurogenesis 1.1e−5
Axon guidance 3.0e−3
Blood vessel development 8.7e−3






IPA IPA Canonical pathways Axonal guidance signaling 5.8e−9
ERK/MAPK signaling 1.8e−4
VEGF ligand-receptor interaction 1.9e−3
TAF15 EMC. Beside ‘generic’ biological processes
(e.g. multicellular organism development, anatomical
structure development), several of the top gene ontology
(GO) terms of both clusters were related to neuroge-
nesis; gene cluster 1, associated with EWSR1 EMC,
also included muscle and circulatory system develop-
ment (DAVID Gene Functional Annotation Tool, see
supplementary material, Table S1A).
To gain a better insight, we then focused on genes
that, besides being statistically differentially expressed
in TAF15 versus EWSR1 tumors, had an absolute
variation greater than 50% (abs.log2 FC> 0.6) (see
supplementary material, Table S1B). Overall, func-
tional annotation with different algorithms highlighted
an enrichment of GO categories associated with axon
guidance, neurogenesis, blood vessel morphogenesis
and muscle system process (Table 2). In particular,
over-representation analyses (ORA-WebGestalt and
DAVID) indicated that nervous system development,
axon guidance, Semaphorin-Plexin signaling pathway,
blood vessel morphogenesis and glutamate receptor
signaling were among the top enriched GO biological
processes (Table 2). Axonal guidance, which includes
various components of VEGFR signaling, was the top
enriched canonical pathway according to IPA. Other
enriched pathways included Reelin, Ephrin and glu-
tamate receptor signaling (Table 2 and supplementary
material, Table S1C–E).
GSEA predicted that neuron development and
axonogenesis were among the categories enriched in
TAF15-positive tumors, whereas muscle system and
extracellular space (that includes several secreted fac-
tors involved in angiogenesis) were among the processes
enriched in EWSR1 EMC (Table 2 and supplementary
material, Table S1F–G).
Axon guidance genes differentially expressed in the
two EMC variants included Reelin (RELN), compo-
nents of the Eph/Ephrin signaling network, semaphorins
(SEMA) and cognate receptors and co-receptors Plexin
(PLXN) and Neuropilin (NRP), as well as other genes
involved in the regulation of the vasculature. In particu-
lar, TAF15 EMC overexpressed class 4–6 SEMA as well
as PLXNA1, PLXNA4, PLXNC1, SLIT1, and ROBO1.
TAF15-positive EMC also overexpressed a number
of other neuron-associated molecules such as SYP,
ELAVL2, NPDC1, SCG3, NEFH, STX1A, and UNC13A.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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Figure 2. Representative EMC immunostainings representative immunostainings for Nestin, Semaphorin 4D, Synaptophysin and Reelin in
a set of EWSR1-NR4A3 (top) and TAF15-NR4A3 (bottom) EMC. Case ID number is indicated. Magnification: ×100.
Table 3. EMC immunoprofile
Case # NR4A3 partner SEMA 4D Plexin A4 Synaptophysin Reelin Nestin CD56 GFAP
1 EWSR1 − + − ++ + +++ −
2 EWSR1 − + +/F ++ + + −
3 EWSR1 − + − +/F ++ − +/F
4 EWSR1 − + − + +/− + +
5 EWSR1 − +/− − + + − +
6 EWSR1 − + − +/− +/F − −
7 EWSR1 − + +/F +/F + +/F +
8 TAF15 + + +/F +/F + − +/F
9 TAF15 +/F +++ + +/F − + −
10 TAF15 ++ +++ ++ + +/− + +
11 TAF15 +/F ++ +/− + +/− − −
12 TAF15 + + ++ + +/− + +/−
−, very weak to negative; +/−, weak; +/F, focal positivity; +, mild; ++, moderate; +++, strong.
Conversely, SEMA3C, SEMA3G, and RELN were more
expressed in EWSR1 tumors (Figure 1C; see supple-
mentary material, Table S1H). This differential expres-
sion trend was corroborated by a targeted transcriptional
array analysis on a subset of cases for which suitable
material was available (data not shown). Immunohis-
tochemical analyses (Figure 2 and Table 3) indicated
an overall positivity of EMC for neuronal markers
(Nestin, CD56/NCAM and GFAP) and confirmed that
SEMA4D, Plexin A4, Synaptophysin (SYP) were
higher in TAF15 compared to EWSR1-translocated
EMC. Conversely, the highest levels of Reelin were
observed among EWSR1 positive tumors.
The type of chimera dictates biology
and transcriptional profile of the two EMC variants
Based on these results, we hypothesized that the type
of chimera dictates the different phenotype of the two
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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EMC variants. To verify this hypothesis, in the absence
of EMC-derived cell cultures, we sought to engineer
sarcoma cell lines for the expression of EWSR1-NR4A3
and TAF15-NR4A3. Unfortunately, while NR4A3 was
well tolerated, most of the cell lines tested (U2-OS,
MES-SA, VA-ES-BJ, HOS, HT-1080) were refractory
to the expression of NR4A3 chimeras (data not shown).
Eventually, tBJ/ER transformed human fibroblasts,
which are an effective model for studying mesenchymal
cell transformation [31], turned out to be a suitable
background. In these cells, ectopic NR4A3 and relative
fusion proteins were expressed both in the nucleus and
in the cytoplasm, with a prevalent nuclear localization
(not shown).
The cell models generated in the tBJ/ER background,
namely EWSR1-NR4A3 (E-N), TAF15-NR4A3 (T-N),
and NR4A3, were tested for their tumorigenic potential
by anchorage-independent growth in soft agar. The
expression of either chimeric protein conveyed an
advantage in terms of colony formation efficiency as
opposed to NR4A3 (Figure 3A). Moreover, the con-
trast T-N versus E-N indicated that cells expressing
TAF15-NR4A3 formed a greater number and larger
colonies. These results were confirmed in independent
biological replicates with untagged and Strep-tagged
versions of the constructs.
Given the more malignant phenotype of T-N cells,
we sought to compare the biological behavior of the
two major TAF15-NR4A3 isoforms detected in human
tumors. Cells were engineered with the T-N* fusion
variant (TAF15 exon 6-NR4A3 exon 3) and with the less
common T-N variant (TAF15 exon 6-NR4A3 intron 2).
Both T-N and T-N* were well expressed at mRNA and
protein level (T-N* even a little more than T-N). T-N
and T-N* were then compared for colony formation effi-
ciency. Under these experimental conditions, T-N* and
T-N were essentially indistinguishable (see supplemen-
tary material, Figure S1).
Transcriptome analysis of the tBJ/ER cell models
revealed a distinct gene expression pattern. In particular,
E-N mapped close to NR4A3 whilst T-N cells clus-
tered apart according to PCA (Figure 3B). Hierarchical
clustering of the top differentially expressed genes
between E-N and T-N (top 500; FDR< 0.1) yielded
two major clusters: cluster 1, composed of genes (240)
overexpressed in E-N and primarily associated with cell
proliferation and vasculature development; cluster 2,
made of genes up-regulated in T-N (260) and including
molecules implicated in nervous system develop-
ment (Figure 3C; supplementary material, Table S2A).
Axonogenesis, nervous system and vasculature develop-
ment were also called when all the genes differentially
expressed in the two cell models (abs.log2 FC> 0.6;
p < 0.05) were functionally annotated (Table 2 and
supplementary material, Table S2B–G).
To address how well these models recapitulated
human EMC, the list of the top significantly differen-
tially expressed genes in T-N versus E-N cells and in the
two tumor variants were intersected, revealing greater
than 10% overlap (170/1500 genes). Not surprisingly,
the shared genes turned out to be implicated in axon
guidance, neurogenesis and angiogenesis (Figure 3D
and supplementary material, Table S2H), strongly sup-
porting a key role of these pathways as discriminant
factors between EWSR1-NR4A3 and TAF15-NR4A3
positive contexts.
Several axon guidance factors such as SEMAs, PLXNs
and EPH/EFN signaling molecules were modulated
in response to the two chimeric genes. Although the
molecules that were differentially expressed in the cell
models were not precisely the same as in EMC, likely
also because of the different cellular background, there
was a remarkable overlap in the modulation of the
classes of axon guidance cues. Specifically, as in tumors,
class 4–6 SEMAs and class 3 SEMAs were in gen-
eral more abundant in T-N and E-N cells, respectively,
with an apparent trend of incremental divergence from
NR4A3 to E-N to T-N (Figure 3E; see supplementary
materials, Figure S2; Table S2I). Moreover, the axonal
factors that were significantly modulated in the two
EMC variants showed a coherent modulation trend also
in T-N versus E-N cells (Figure 3F). These data were
confirmed by RT-qPCR assays on independent biolog-
ical replicates of tBJ/ER expressing NR4A3, E-N and
T-N (with T-N and T-N* yielding similar results) (see
supplementary material, Figure S2).
NR4A3 chimeras differentially bind the SEMA3C
promoter
An in silico analysis (MatInspector) identified sev-
eral potential NR4A3 recognition sites on the regula-
tory regions of SEMA genes. In particular, SEMA3C,
which is differentially expressed in both EMC and cell
models, turned out to harbor a consensus sequence
targeted by NR4A3 to regulate CCND1 (CyclinD1)
(Figure 4A) [34]. To explore the possibility of a direct
transcriptional control of NR4A3 over this gene, we
performed ChAP assays coupled with target-specific
amplification (ChAP-qPCR) on tBJ/ER cells engineered
to express Strep-tagged NR4A3, EWSR1-NR4A3 or
TAF15-NR4A3. ChAP-qPCR experiments confirmed
the ability of NR4A3 to bind the predicted target on
SEMA3C. More interestingly, the ability of NR4A3
to recognize the SEMA3C target region was retained
by the EWSR1-NR4A3 chimera but was impaired by
TAF15-NR4A3 (Figure 4B), in line with transcriptional
profiling data.
NR4A3 chimeric proteins are expressed at different
extents
Intriguingly, in generating multiple biological replicates
of the cell models, we realized that the EWSR1-NR4A3
chimeric protein tended to be expressed at lower lev-
els than TAF15-NR4A3 despite essentially comparable
mRNA levels (Figures 4C, D and S3). This discrepancy
in RNA/protein levels was not attributable to a physi-
ological experimental variability, as it was observed in
multiple independent biological replicates with different
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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Figure 3. Transcriptome profiling of E-N, T-N and NR4A3 cell models. (A) Top: Representative phase-contrast images showing colony
formation in soft agar of tBJ/ER cells engineered to express control empty vector (Ctrl), NR4A3, E-N or T-N. Magnification: ×100; scale
bar= 200 μm. The plot (bottom) shows mean number of colonies >30 μm± SE (black bars) and mean colony size± SE (gray bars) per ×100
magnification field at day 8 post-plating. (B) PCA of the transcriptome of NR4A3 (black), E-N (red) and T-N (blue) cell models. (C) Z-score
normalized heat map of the top 500 differentially expressed genes in T-N versus E-N cells. Sample (top) and gene (left) dendrograms are
shown. Color-coding is as in Figure 1. Gene cluster 1 consists of the genes overexpressed in E-N; gene cluster 2, genes overexpressed in T-N.
(D) Network integration analysis of genes differentially expressed in both EMC (TAF15-NR4A3 versus EWSR1-NR4A3) and in cell models
(T-N versus E-N). Axon guidance-associated GO biological processes are highlighted in blue. (E) Heat map and hierarchical clustering
for the axon guidance molecules that are differentially expressed in T-N versus E-N. NR4A3 co-clusters with E-N. (F) Plot showing the
modulation in tBJ/ER T-N versus E-N cells (black bars) of the axon guidance cues that were detected as statistically differentially expressed
in TAF15-NR4A3 versus EWSR1-NR4A3 EMC (grey bars). *Genes whose modulation (Log2 fold change) is statistically significant also in cell
models (p < 0.05).
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Figure 4. NR4A3 chimeras differentially bind the SEMA3C promoter and display diverse protein expression levels. (A) Schematic represen-
tation of the putative NR4A3 binding site identified by MatInspector on the human SEMA3C regulatory region. The NBRE-like sequence and
genomic coordinates are shown (human genome assembly GRCh38/hg38; chromosome 7). Arrows indicate the primers used in ChAP-qPCR
assays. (B) ChAP-qPCR results of the binding of NR4A3 and NR4A3 chimeras to the indicated SEMA3C regulatory region. Relative enrich-
ment for the SEMA3C NBRE target region in tBJ/ER cells expressing Strep-tagged NR4A3, E-N or T-N versus negative control (empty vector,
Ctrl) is shown. Relative enrichment indicates the amount of SEMA3C-specific precipitated DNA normalized to the total input chromatin,
with Ctrl set to 1. (C) Representative immunoblot for NR4A3 in tBJ/ER cells engineered to express EWSR1-NR4A3, TAF15-NR4A3, NR4A3,
or control empty vector (Ctrl). The blot was hybridized with an anti-N-terminus MoAb (clone H7833). *Nonspecific band. (D) Relative
expression levels of NR4A3-related mRNAs (±SE) assessed by RT-qPCR of the cells shown in (C).
vectors and cellular backgrounds, and it was indepen-
dent of the type of antibody used (anti-N-terminus or
anti-C-terminus NR4A3; anti-Strep). EWSR1-NR4A3
protein appeared to underexpressed also when compared
to NR4A3, but in this case the difference was at least
in part correlated to mRNA levels (Figure 4C,D and see
supplementary material, Figure S3). Unfortunately, the
lack of reliable antibodies validated for the detection
by IHC of NR4A3 fusion proteins prevented us from
assessing NR4A3 chimeric proteins in human tumors.
Discussion
This study aimed at shedding light on the patho-
biology of EMC, a sarcoma histotype of uncertain
differentiation and unpredictable clinical behavior.
Here we report that EMC expressing TAF15-NR4A3
or EWSR1-NR4A3 display a distinct transcriptional
profile. More importantly, we provide evidence that
this different transcriptional pattern can be mimicked
in vitro by ectopic expression of the cognate chimera
in oncogene-transformed human fibroblasts, indicating
that the type of NR4A3 fusion variant dictates the biol-
ogy of EMC subtypes. Indeed, TAF15-NR4A3 positive
cell models displayed a more pronounced tumorigenic
phenotype than EWSR1-NR4A3 cells, as assessed by
anchorage independent growth. This result is in line
with the claimed more aggressive clinical behavior of
TAF15-NR4A3 EMC [12].
Both in tumors and cell models, ‘axon guidance’
and ‘neurogenesis’ were among the main func-
tional categories that marked the difference between
TAF15-NR4A3 and EWSR1-NR4A3 transcriptomes.
NR4A3 has been associated with these pathways
previously [35], but the mechanism through which
NR4A3 impinges upon these phenomena is still poorly
defined. We found that this intrinsic function is differ-
entially tuned when NR4A3 fuses with either TAF15 or
EWSR1, yielding a different biological outcome.
In particular, compared to EWSR1-translocated
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
10 M Brenca, S Stacchiotti, S Pilotti, R Maestro et al
EMC, TAF15-NR4A3 tumors tended to overexpress
pro-tumorigenic class 4, 5 and 6 SEMAs whilst most
class 3 SEMAs appeared to be underexpressed. The
same trend was confirmed in cell models engineered to
express the two chimeric genes.
Originally identified as one of the critical processes
related to connectivity during nervous system devel-
opment, the axon guidance pathway was subsequently
implicated in cancer, due to its involvement in cell pro-
liferation, apoptosis, adhesion, migration, angiogenesis,
and modulation of immune response [36–39]. Several
constituents of this pathway have been found to be tran-
scriptionally or structurally altered in tumors, and recent
genomic studies implicate axon guidance as one of the
most commonly affected pathways in cancer [40].
SEMAs represent a family of over 20 secreted (class
3 and in part class 4) and membrane-bound (class
4, 5, 6, 7) proteins that work in concert with their
cognate receptors (PLXNs) and co-receptors (NRPs).
By signaling to downstream kinases and GTPases,
the SEMA/PLXN axis, together with EPH/EFN and
SLIT/ROBO, modulate cytoskeletal dynamics and sig-
nal transduction. Furthermore, by impinging upon the
extracellular milieu, they act as pleiotropic regulators
of tissue homeostasis [41,42]. These axon guidance
molecules are essentially bi-functional as they can
exhibit both attractive and/or repulsive activities [43].
In the context of cancer, secreted class 3 SEMAs
are in general considered to negatively regulate cell
growth and angiogenesis [36,44,45]. Accordingly,
several class 3 SEMAs are reported to be inactivated
or down-regulated in tumors, which correlates with
dismal prognosis [44]. In contrast, class 4–6 SEMAs
are considered oncogenic, providing pro-survival and
pro-angiogenic signals [36,44,46,47], and are often
overexpressed in aggressive forms of cancer [44,46,48].
Besides class 4–6 SEMAs, TAF15-NR4A3 EMC also
overexpressed other axon guidance-related molecules
associated with poor outcome, including PLXNA1,
CXCR4, and EPH/EFN factors [49–52].
Several semaphorins and plexins have been inves-
tigated as potential targets for drugs to treat cancer.
In particular, a humanized antibody directed against
SEMA4D (VX15/2503) has been generated recently and
is currently in phase I/II clinical trials for the treat-
ment of advanced refractory solid tumors. This antibody
has demonstrated immune-mediated antitumor effects in
tumor bearing mice [53]. Thus, blocking the activity of
SEMA4D might represent a novel therapeutic strategy
for TAF15-NR4A3 positive EMC.
The SEMA switch detected in the cell models, which
mirrors that observed in tumors, supports the notion that
the type of fusion plays a key role in this axon guid-
ance reprogramming. In an effort to gain insights on
the mechanisms through which NR4A3 chimeric pro-
teins differentially impact on axon guidance signaling,
we explored the possibility of direct control of SEMA
transcription. We identified an NR4A3 binding site in
the regulatory region of SEMA3C and demonstrated
that both NR4A3 and EWSR1-NR4A3 efficiently bound
this sequence whilst TAF15-NR4A3 was impaired in
this function. This result parallels SEMA3C expression
(upregulated in EWSR1 versus TAF15 EMC and cell
models) and suggests that the diverse fusion partners
differentially tune the ability of NR4A3 to access its
transcriptional targets.
On the other hand, mounting evidence points to
extranuclear functions of NR4A proteins [16]. In this
regard, it has been reported recently that NR4A1 mod-
ulates the function of SEMA3E/PLXND1 complexes
by directly binding PLXND1 and displacing SEMA3E
[54]. This result, which draws attention to the poorly
characterized cytosolic activities of these orphan recep-
tors, discloses the possibility that NR4A3 and relative
chimeras may also interfere with axon guidance signal-
ing via a similar mechanism.
Intriguingly, in generating independent replicates of
the cell models, we observed that although the RNA
levels for the two fusion genes were essentially com-
parable, the TAF15-NR4A3 protein was expressed at
higher levels than EWSR1-NR4A3. These results indi-
cate that the N-terminus FET component, EWSR1 or
TAF15, likely affects the expression of the chimeric
protein at the post-transcriptional level. Indeed, dur-
ing neural differentiation a dichotomy in RNA/protein
amounts has been observed for EWSR1, but not for
TAF15, indicating a differential post-transcriptional reg-
ulation [55]. Based on the above data, it is possible that
the observed phenotypes may be due, at least in part,
to the different protein levels of the chimeras. Never-
theless, we believe that EWSR1 and TAF15 contribute
to the biological properties of the cognate chimera
also through specific, qualitative mechanisms. In fact,
despite lower protein levels, EWSR1-NR4A3 is more
potent than NR4A3 in soft-agar assays and in the
modulation of axon guidance cues. This is in line
with previous findings indicating that, compared to
NR4A3, fusion with EWSR1 increases transcriptional
activity and conveys different specificities to the chimera
[16,56]. Moreover, although expressed at higher levels
than EWSR1-NR4A3, TAF15-NR4A3 is defective in
SEMA3C promoter binding.
As an interesting side note, the axon guidance axis
is known to intersect signaling mediated by receptor
kinases. In particular, secreted SEMA/PLXN have
been reported to interact with and activate a number
of tyrosine kinases, including MET and VEGFR [57].
The connection of NR4A receptors to SEMA/PLXN
and the crosstalk with receptor kinases is particularly
interesting in the light of the therapeutic activity of
sunitinib in EMC [3]. Although small, the study hinted
at a correlation between response and type of fusion,
with TAF15-NR4A3 EMC being unresponsive [3].
Thus, activation of distinct sets of axon guidance cues
by the two chimeras might result in a broader effect
on receptor signaling pathways, thus affecting the
response to suntinib. Noteworthy, in vivo administration
of soluble SEMA3A extends the therapeutic window
of sunitinib in a mouse tumor model by counteracting
sunitinib-induced hypoxia [58]. Since EWSR1-NR4A3
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EMC overexpress class 3 SEMAs, the release of these
soluble factors might contribute to their sensitivity to
sunitinib.
In summary, our work highlights that the type of
NR4A3 fusion protein affects tumor cell phenotype and
dictates the engagement of different axon guidance cues
which are expected to impact on tumor clinical behavior.
Besides providing novel insights on the biology of EMC,
these findings may lay down the basis for the develop-
ment of improved criteria for patient stratification and
disclose novel therapeutic avenues.
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